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1. Introduction
Cardiovascular diseases (CVDs) remain the leading cause of death in modern societies. The
primary cause of dramatic clinical events of CVDs, such as unstable angina, myocardial in‐
farction and stroke, is the atherosclerotic process [1,2,3].
The pathophysiological mechanisms of atherosclerosis are complicated and the integrated
picture of the disease process is not yet complete, so currently is largely investigated. It is
widely recognized that oxidative stress,  lipid deposition, inflammation, Vascular smooth
muscle cells (VSMCs) differentiation and endothelial dysfunction play a critical role in the
formation, progression and eventually rupture of the atherosclerotic plaque [4]. Multiple risk
factors have been associated with the development of atherosclerotic lesions; these include
diabetes mellitus, hypertension, obesity and tobacco smoking. The risk factors are influenced
by genetic predisposition, but also by environmental factors, particularly diet. Moreover, ag‐
ing promotes physiological changes, such as oxidative stress, inflammation and endothelial
dysfunction strictly associated with the pathophysiology of atherosclerosis [5].
The common belief that signs of atherosclerosis and CVDs are clinically relevant only dur‐
ing adult and elderly age is gradually changing, increasing evidence supports that athero‐
genesis is initiated in childhood [6].
Low-density lipoproteins (LDL) are crucial to the development of atherosclerotic lesions,
whereas high-density lipoproteins (HDL) are inhibitors of the process, primarily through
the process of reverse cholesterol transport [4,7]. Dysfunctional lipid homeostasis plays a
central role in the initiation and progression of atherosclerotic lesions. Oxidized-LDL (ox-
LDL) induces endothelial dysfunction with focal inflammation which causes increased ex‐
pression of atherogenic signaling molecules that promote the adhesion of monocytes and T
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lymphocytes to the arterial endothelium and their penetration into the intima. Early stages
of plaque development involve endothelial activation induced by inflammatory cytokines,
ox-LDL and/or changes in endothelial shear stress [8,9]. The monocyte-derived macrophag‐
es, by taking up ox-LDL, become foam cells, which are typical cellular elements of the fatty
streak, the earliest detectable atherosclerotic lesion [10].
After initial injury, different cell types, including endothelial cells, platelets and inflammato‐
ry cells release growth factors and cytokines that induce multiple effects: oxidative stress,
inflammation, VSMCs differentiation from the contractile state to the active synthetic state
and then proliferate and migrate in the subendothelial space [11,12]. Inflammatory cell accu‐
mulation, migration and proliferation of VSMCs, as well as the formation of fibrous tissue,
lead to the enlargement and restructuring of the lesion, with the formation of an evident fi‐
brous cap and other vascular morphological changes [2,13]. Atherosclerotic plaques result
from the progressive accumulation of cholesterol and lipids in oxidized forms, extracellular
matrix material and inflammatory cells [14]. In fact, atherosclerosis manifests itself histologi‐
cally as an arterial lesions known as plaques, which have been extensively characterized:
plaques contain a central lipid core that is most often hypocellular and may include crystals
of cholesterol that have formed in the foam cells. The lipid core is separated from the arterial
lumen by a fibrous cap and myeloproliferative tissue that consists of extracellular matrix
and VSMCs. Advanced lesions can grow sufficiently large to block blood flow and so devel‐
op an acute occlusion due to the formation of thrombus or blood clot resulting in the impor‐
tant and severe cardiovascular clinical events [2,10].
Figure 1. Main vascular alterations observed during atherogenesis. LDL: low density lipoprotein; HDL: high density lip‐
oprotein.
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2. Atherosclerosis and oxidative stress
Oxidative stress is defined as an imbalance between pro-oxidant and anti-oxidant factors in
favour of pro-oxidants and is central to the pathophysiology of atherosclerosis. The analysis
of plaque composition has revealed products of protein and lipid oxidation, such as chlori‐
nated, nitrated amino acids, lipid hydroperoxides, short-chain aldehydes, oxidized phos‐
pholipids, F2α-isoprostanes and oxysterols [15].
Excessive production of reactive oxygen species (ROS) during oxidative stress, out stripping
endogenous anti-oxidant defence mechanisms, has been implicated in processes in which
they oxidize and damage DNA, protein, carbohydrates and lipids. There are multiple poten‐
tial enzymatic sources of ROS, including mitochondrial respiratory cycle, heme, arachidonic
acid enzyme, xanthine oxidase, nitric oxide synthese and others. However, the predominant
ROS-producing enzyme in the VSMCs and in the myocardium is NADPH oxidase, that
plays a pivotal role in the atherogenesis [16].
Figure 2. Generation and main damages induced by ROS. Modified from [17]. O2-: superoxide; HO`: hydroxyl; H2O2:
hydrogen peroxide..
ROS may contribute to LDL oxidation, inflammation, local monocyte chemoattractant pro‐
tein production, upregulation of adhesion molecules and macrophages recruitment, endo‐
thelial dysfunction, platelet aggregation, extracellular matrix remodelling through collagen
degradation, thus playing a central role in the development and progression of atheroscle‐
rosis  and  eventually  in  plaque  rupture  [17,18,19].  Several  oxidative  systems  potentially
contribute to LDL oxidation in vivo, included NADPH oxidases, xanthine oxidase, myelo‐
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peroxidase,  uncoupled  nitric  oxide  synthase,  lipoxygenases  and  mitochondrial  electron
transport chain [20,21,22]. Ox-LDL particles exhibit multiple atherogenic properties, which
include uptake and accumulation of macrophages, as well as pro-inflammatory, immuno‐
genic, apoptotic and cytotoxic activities, induction of the expression of adhesion molecules
on endothelial cells, promotion of monocyte differentiation into macrophages, production
and release of pro-inflammatory cytokines and chemokines from macrophages [14].
In particular, at endothelial level, ROS regulates numerous signaling pathways including
those regulating growth, proliferation, inflammatory responses of endothelial cells, barrier
function and vascular remodeling; while at VSMC level, ROS mediates growth, migration,
matrix regulation, inflammation and contraction [23,24,25], all are critical factors in the pro‐
gression and complication of atherosclerosis.
A vicious cycle between oxidative stress and oxidative stress-induced atherosclerosis leads
to the development and progression of atherosclerosis.
Figure 3. Role of ROS and oxidative stress in the atherosclerosis. Modified from [24]. O2: oxygen; O2-: superoxide; H2O2:
hydrogen peroxide; VSMC: vascular smooth muscle cell.
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3. Atheroprotective strategies
Recently, various pharmacological therapies have been designed to reduce the development
and progression of the atherosclerotic plaque and remarkable therapeutic advances in the
treatment of CVDs have been made with insulin sensitizers, statins, inhibitors of the renin-
angiotensin system and anti-platelet agents [19,26]. However, strictly control of cardiovascu‐
lar risk factors are often difficult to obtain and the progression of atherosclerosis has not
been completely prevented with current pharmacological therapeutic options. Moreover,
the modern evolution of Western societies seemingly steers populations towards a profound
sedentary lifestyle and incorrect diet is becoming difficult to reverse. Understanding of the
mechanisms that explain the fatal effects of physical inactivity and incorrect diet, the benefi‐
cial effects of an healthy lifestyle remains largely unexplored [3].
Concerning atherosclerosis prevention by foods, dietary supplements and healthy life style
may provide prevention and/or treatment to the onset and development of atherosclerosis.
Development of an atheroprotective strategy acting on oxidative stress involved in the
pathogenesis of atherosclerosis and with little toxicity or adverse effects may provide an ide‐
al therapeutic treatment for atherosclerosis. Actually, numerous studies have investigated
the prevention and treatment of atherosclerosis using naturally-occurring anti-oxidants.
In this review we summarize the many pieces of the puzzle to identified molecular targets
for prevention and therapy against atherosclerosis and present that a healthy life style has
natural anti-atherogenic activity which has been forgotten by modern societies.
Figure 4. Potential atheroprotective role of anti-oxidants in the atherogenic process. Modified from [27]. ox-LDL: oxi‐
dized-low density lipoprotein; ROS: reactive oxygen species.




Physical activity is currently recognized as a potent tool for the prevention of chronic degen‐
erative diseases, including CVDs and common tumors, such as those affecting the colon,
breast, prostate and endometrium [28].
There is a body of clinical and experimental evidence showing that voluntary and imposed
physical exercise prevents the progression of CVDs and reduces cardiovascular morbidity
and mortality. Therefore a physically active state is an appropriate and natural biological
condition for human and most animal species [3].
It has been demonstrated that exercise slows the progression of atherosclerosis, promoting
its stabilization and preventing plaque rupture in a variety of hypercholesterolaemic animal
models, such as apolipoproteinE-deficient mice and LDL receptor-deficient mice, whereas
physical inactivity accelerates it [3,29].
Exercise  increases  blood  anti-oxidant  capacity  through  elevating  hydrophilic  anti-oxi‐
dants  (uric  acid,  bilirubin and vitamin C) and decreases lipophilic  anti-oxidants (carote‐
noids  and  vitamin  E)  [28].  It  is  noteworthy  that  exercise  prevents  plaque  vulnerability
and atherosclerosis progression without necessarily correcting classic risk factors, such as
hypercholesterolaemia,  endothelial  dysfunction and high blood pressure,  suggesting that
exercise  can  directly  affect  plaque  composition  and phenotype,  thus  preventing  the  ap‐
pearance of fatal lesions. Besides the effect of diet and drugs, the protective role of regu‐
lar  exercise  against  atherosclerosis  is  well  established and its  beneficial  atheroprotective
effects are not limited to one particular cell, but to a variety of cells and tissues involved
in the pathogenesis of atherosclerosis and metabolic disorders, such as macrophages and
adipose tissue [3].
Regular exercise and a correct diet would be natural atheroprotective approaches which has
been forgotten by modern societies.
5. Diet
Several epidemiological studies suggest that a correct diet is significantly associated with
reduced risks of CVDs. Phytochemicals including polyphenols like flavonoids, resveratrol
and ellagitannins have been shown to be associated with lower risks of CVDs [30,31]. In
fact,  they  are  potent  anti-oxidants  and  anti-inflammatory  agents,  thereby  counteracting
oxidative  damage  and inflammation.  Actually,  dietary  anti-oxidants  have  attracted  con‐
siderable  attention  as  preventive  and  therapeutic  agents.  There  is  adequate  evidence
from observational in vitro,  ex vivo  and in vivo  studies that consumption of certain foods
results  to  a  reduction  in  oxidative  stress  [27].  Evidence  linking  dietary  anti-oxidants  to
atherosclerosis in humans is still circumstantial and although in some studies the associa‐
tion of  anti-oxidant  intake  and low risk  for  atherosclerosis  is  perceptible,  in  others  this
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association cannot be established. The inconsistency of the results reflects the limitations
of human studies, the diet differences, the pre-existing total anti-oxidant status, the stage
of  disease,  the interaction between dietary modulation and genetic  composition of  indi‐
viduals,  the dosage and duration of supplementation, the age and the sex. On the other
hand, studies in animal models of atherosclerosis clearly show an atheroprotective effect
of  dietary anti-oxidants,  however,  they focus mainly on early atherosclerotic  events and
not in advanced atherosclerosis as in humans [27].
Cardiovascular prevention and treatment strategies should consider the simple, direct and
inexpensive dietary approach as a first-line strategy to the burgeoning burden of CVDs,
alone or in combination with pharmalogic treatments [10].
In this review we focus our attention on the main natural anti-oxidants contained in food
and on their primary diet source.
6. Polyphenol
Polyphenols are the most abundant anti-oxidants in human diet and are common constitu‐
ents of foods of plant origin and are widespread constituents of fruits, vegetables, cereals,
olive, legumes, chocolate and beverages, such as tea, coffee and wine [32,33].
They are defined according to the nature of their backbone structures: phenolic acids, flavo‐
noids and the less common stilbenes and lignans. Among these, flavonoids are the most
abundant polyphenols in the diet [34]. Despite their wide distribution, the health effects of
dietary polyphenols have been attentively studied only in recent years [32] and several stud‐
ies, although not all, have found an inverse association between polyphenol consumption
and CVDs motality [35].
Polyphenols  exert  anti-atherosclerotic  effects  in the early stages of  atherosclerosis  devel‐
opment, they decrease LDL oxidation, improve endothelial function, increase vasorelaxa‐
tion,  modulate  inflammation  and  lipid  metabolism,  improve  anti-oxidant  status  and
protect  against  atherothrombotic  events  including  myocardial  ischemia  and  platelet  ag‐
gregation [35].
Many  polyphenols  have  direct  anti-oxidant  properties,  acting  as  reducing  agents,  and
may react  with  reactive  chemical  species  forming products  with  much lower  reactivity.
Polyphenols may also affect indirectly the redox status by increasing the capacity of en‐
dogenous  anti-oxidants  or  by  inhibiting  enzymatic  systems  involved  in  ROS  formation
[36].  The  free-radical  scavenging  activity  of  many polyphenols  has  been  reported to  be
much stronger than that of vitamin C, vitamin E or glutathione, the major anti-oxidants
present in the body.
In spite of their potent protective effects in the development of atherosclerosis, little is
known about aortic distribution of polyphenols [34].
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Figure 5. Main atheroprotective mechanisms exert by polyphenols. VSMC: vascular smooth muscle cell; LDL: low den‐
sity lipoprotein; ROS: reactive oxygen species.
6.1. Resveratrol
Resveratrol naturally occurs as a polyphenol found in grapes and grape products, including
wine, as well as other sources, like nuts [37]. In grapes, resveratrol is present in the skin as
both free resveratrol and piceid.
Initially characterized as a phytoalexin, a toxic compound produced by higher plants in re‐
sponse to infection or other stresses, such as nutrient deprivation, resveratrol attracted little
interest until 1992 when it was postulated to explain some of the cardioprotective effects of
red wine [36].
Treatment with resveratrol has been found to reduce oxidative stress and increase the activi‐
ties of several anti-oxidant enzymes including superoxide dismutase, catalase, glutathione,
glutathione reductase, glutathione peroxidase and glutathione-5-transferase [38]. Resvera‐
trol also prevents the oxidation of polyunsaturated fatty acids found in LDL and inhibits the
ox-LDL uptake in the vascular wall in a concentration-dependent manner, as well as pre‐
vents damage caused to lipids through peroxidation [38]. These effects were found to be
stronger respect the well known anti-oxidant vitamin E. Moreover, resveratrol has been pro‐
posed to influence and maintain a balance between production of vasodilatators and vaso‐
costrictors respectively [38,39], thereby preventing platelet aggregation and oxidative stress,
which leads to reduction in CVD risk [40].
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Resveratrol so has been demonstrated to exert a variety of health benefits including anti-
atherogenic, anti-inflammatory and anti-tumor effects. These positive effects are attributed
mainly to its anti-oxidant and anti-coagulative properties.
Figure 6. Main atheroprotective mechanisms exert by resveratrol. LDL: low density lipoprotein; HDL: high density lipo‐
protein; ROS: reactive oxygen species.
Resveratrol reduced not only vascular lipid levels, including LDL and triglycerides, but also
the myocardial complications by influencing infarct size, apoptosis and angiogenesis. In ad‐
dition, resveratrol feeding prevented steatohepatitis induced by atherogenic diets through
modulation of expression of genes involved in lipogenesis and lipolysis, reduced total and
LDL levels, while increasing HDL levels in plasma.
Several investigations with human and various animal model have demonstrated an ab‐
sence of toxic effects after supplementation with resveratrol across a wide range of dos‐
ages [38].
Promising findings by several groups have demonstrated the potential cardioprotection of
resveratrol by reducing atherosclerotic plaque onset and formation.




Flavonoids, many of which are polyphenolic compounds, are believed to be beneficial for
the prevention and treatment of atherosclerosis and CVDs mainly by decreasing oxidative
stress and increasing vasorelaxation [32,40,41]. More than 8.000 different flavonoids have
been described and since they are prerogative of the kingdom of plants, they are part of
human diet  with  a  daily  total  intake  amounting  to  1  g,  which  is  higher  than  all  other
classes of phytochemicals and known dietary anti-oxidants. In fact, the daily intake of vita‐
min C, vitamin E and β-carotene from food is estimated minor of 100 mg. A number of dif‐
ferent  factors,  such  as  harvesting,  environmental  factors  and  storage,  may  affect  the
polyphenol content of plants. Additional variability in flavonoid content could be expected
in finished food products because its availability is largely dependent on the cultivar type,
geographical origin, agricultural practices, post-harvest handling and processing of the fla‐
vonoid containing ingredients [32].
Flavonoids are widely distributed in the plant and are categorized as flavonol, flavanol, fla‐
vanone, flavone, anthocyanidin and isoflavone. Quercetin is one of the most widely distrib‐
uted flavonoids, which are abundant in red wine, tea and onions. Quercetin intake is
therefore suggested to be beneficial for human health and its anti-oxidant activity should
yield a variety of biological effects.
The major flavanols in the diet are catechins. They are abundant in green tea (about 150mg/
100ml) and lesser extent in black tea (13.9 mg/100 ml) where parent catechins are oxidized
into complex polyphenols during fermentation. Red wine (270 mg/L) and chocolate (black
chocolate: 53.5 mg/100 g; milk chocolate: 15.9 mg/100 g) are also sources of catechins [34].
Polyphenols and/or flavonoids exhibit a variety of beneficial biological effects, including an‐
ti-oxidant, anti-hypertensive, anti-viral, anti-inflammatory and anti-tumor activities; more‐
over some flavonoids have also been reported to modulate insulin resistance, endothelial
function and apoptosis [32,41].
Many studies have shown that flavonoids demonstrate protective effects against the initia‐
tion and progression of atherosclerosis. The bioactivity of flavonoids and related polyphe‐
nols appears to be mediated through a variety of mechanisms, though particular attention
has been focused on their direct and indirect anti-oxidant actions. In particular, it has been
shown that the consumption of flavinoids limits the development of atheromatous lesions,
inhibiting the oxidation of LDL, which is considered a key mechanism in the endothelial le‐
sions occurring in atherosclerosis.
Mechanisms of anti-oxidant effects include also: suppression of ROS formation either by in‐
hibition of enzymes or chelating trace elements involved in free radical production, scaveng
ROS and upregulation or protection of anti-oxidant defences [32]. The phenolic hydroxyl
groups of flavonoids, which act as electron donors, are responsible for free radical scaveng‐
ing activity [27,40].
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Since the evidence of therapeutic effects of dietary flavinoids continues to accumulate, flavi‐
noids could be considered as anti-oxidant nutrients available in everyday life as a protective
tool for prevention of atherosclerosis.
Figure 7. Main atheroprotective mechanisms exert by flavinoids. LDL: low density lipoprotein.
7. Green tea
Tea, a beverage consumed worldwide, is a source of both pleasure and healthful benefits.
Originally recommended in traditional Chinese medicine, green tea (Camellia sinensis) has
gained considerable attention due to its anti-oxidant, anti-inflammatory, anti-hypertensive,
anti-diabetic and anti-mutagenic properties [42].
Green tea constitutes 20%-22% of tea production and is principally consumed in China, Ja‐
pan, Korea and Morocco. Green tea, or non-fermented tea, contains the highest amount of
flavonoids, in comparison to its partially fermented (oolong tea) and fermented (black tea)
counterparts and, due to its high content of polyphenolic flavonoids, has shown unique car‐
diovascular health benefits. In green tea, catechins comprise 80% to 90% of total flavonoids,
with epigallocatechin gallate, being the most abundant catechin (48–55%), followed by epi‐
Atherosclerosis and Current Anti-Oxidant Strategies for Atheroprotection
http://dx.doi.org/10.5772/53035
11
gallocatechin (9–12%), epicatechin gallate (9–12%) and epicatechin (5–7%) [42]. The catechin
content of green tea depends on several factors including how the leaves are processed be‐
fore drying, preparation of the infusion and decaffeination, as well as the form in which it is
distributed in the market (instant preparations, iced and ready-to-drink teas have been
shown to contain fewer catechins) [43]. When tea leaves are rolled or broken during indus‐
try manufacture, catechins come in contact with polyphenol oxidase, resulting in their oxi‐
dation and the formation of flavanol dimers and polymers known as theaflavins and
thearubigins [44].
Tea leaves destined to become black tea are rolled and allowed to ferment, resulting in rela‐
tively high concentrations of theaflavins and thearubigins and relatively low concentrations
of catechins. Consequently, green tea contains relatively high concentrations of catechins
and low concentrations of theaflavins and thearubigins. It is important to underline that
black tea administration to LDL receptor-deficient mice did not affect aortic fatty streak le‐
sion area, although fatty streak lesion areas in the same animal model supplemented with
anti-oxidants, such as vitamin C, vitamin E and β-carotene, were 60% smaller than those of
control animals [44,45]. On the other hand, green tea catechins have been shown to inhibit
formation of ox-LDL, may decrease linoleic acid and arachidonic acid concentrations [46],
elevate serum anti-oxidative activity and prevent or attenuate decreases in anti-oxidant en‐
zyme activities [44]. In addition to having anti-oxidant properties, green tea catechins have
also been shown to reduce VSMCs proliferation [42].
In particular, Erba et al. (2005) showed a significant decrease in plasma peroxide levels,
DNA oxidative damage and LDL oxidation, as well as a significant increase in total anti-oxi‐
dant activity in the plasma of healthy volunteers who consumed two cups of green tea per
day in addition to a balanced and controlled diet demonstrating that green tea may act syn‐
ergistically with a correct diet in affecting the biomarkers of oxidative stress [47]. Much of
the evidence supporting anti-oxidant functions of tea polyphenols is derived from assays of
their anti-oxidant activity in vitro. However, evidence that tea polyphenols are acting direct‐
ly or indirectly as anti-oxidants in vivo is more limited [44].
It is very important to underline also that while green tea beverage consumption is con‐
sidered part  of  a  healthy  lifestyle,  green  tea  extracts  supplements  should  be  used with
caution. Very high doses of green tea extracts (6 g–240 g) have been associated with hepa‐
totoxicity in patients who used them for a duration of 5 to 120 days, changing in blood bi‐
ochemical parameters included an elevation of serum levels of aspartate aminotransferase,
alanine  aminotransferase,  alkaline  phosphatase,  total  bilirubin  and  albumin  levels.  Al‐
though, it was observed a reversal of symptoms when subjects stopped taking the green
tea supplement [42].
In addition, in a number of countries, tea is commonly consumed with milk. Interactions be‐
tween tea polyphenols and proteins found in milk have been found to diminish total anti-
oxidant capacity in vitro, but it is presently unclear whether consuming tea with milk
substantially alters the biological activities of tea flavonoids in vivo. The addition of milk to
tea did not significantly alter areas under the curve for plasma catechins or flavonols in hu‐
man volunteers, suggesting that adding milk to tea does not substantially affect the bioavail‐
Current Trends in Atherogenesis12
ability of tea catechins or flavonols. Two studies in humans found that the addition of milk
decreased or eliminated increase in plasma anti-oxidant capacity induced by tea consump‐
tion, whereas another found no effect [44].
Nevertheless, a diet rich in foods containing anti-oxidant polyphenols, like green tea bever‐
ages, combined with physical activity and a correct diet may offer primary prevention
against CVDs. While future clinical trials could further elucidate the cardioprotective bene‐
fits of green tea beverages, on the basis of existing reports, freshly prepared green tea ap‐
pears to be a healthy dietary choice to consider as an atheroprotective strategy.
8. Herbal
Studies of the herbal medicines for the prevention and treatment of atherosclerosis have re‐
ceived much attention in recent years. Single compounds isolated from some herbal materi‐
als have been shown to reduce the production or remove the build up of cholesterol in vitro
or in vivo studies. Glabrol from Glycyrrhiza glabra has been found to be an acyl-coenzyme
A: a cholesterol acyltransferase inhibitor that blocks the esterification and intestinal absorp‐
tion of free cholesterol. Curcumin from Curcuma longa inhibited cholesterol accumulation.
Puerarin from Pueraria lobata can promote cholesterol excretion into bile by upregulating
the rate-limiting enzyme in the synthesis of bile acid from cholesterol. Moreover, these ex‐
tracts have anti-oxidative effects and may reduce the levels of ox-LDL and increased the lev‐
els of HDL [48].
9. Pomegranate juice
Pomegranate juice consumption slowed atherosclerosis progression through the potent anti-
oxidant properties of pomegranate polyphenols [35].
Pomegranate fruit (Punica granatum L.) has been rated to contain the highest anti-oxidant ca‐
pacity in its juice, when compared to other commonly consumed polyphenol rich beverages.
The anti-oxidant capacity of pomegranate juice was shown to be three times higher than that
of red wine and green tea, based on the evaluation of the free-radical scavenging and iron
reducing capacity [30]. It was also shown to have significantly higher levels of anti-oxidants
in comparison to commonly consumed fruit juices, such as grape, cranberry, grapefruit or
orange juice. The principal anti-oxidant polyphenols in pomegranate juice are ellagitannins
and anthocyanins. Ellagitannins account for 92% of the anti-oxidant activity of pomegranate
juice and are concentrated in peel, membranes and piths of the fruit. The bioavailability of
pomegranate polyphenols is affected by several factors, including: interindividual variabili‐
ty, differential processing of pomegranate juice, as well as the use of analytical techniques
sensitive enough to detect low postprandial concentrations of these metabolites [30].
One pomegranate fruit contains about 40% of an adult’s recommended daily requirement of
vitamin C and is high in polyphenol compounds. The pomegranate plant contains alkaloids,
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mannite, ellagic acid and gallic acid and the bark and rind contain various tannins. The pol‐
yphenols in pomegranate are believed to provide the anti-oxidant activity and protect LDL
against cell-mediated oxidation directly by interaction with the LDL [49]. In fact, the supple‐
mentation of pomegranate juice revealed a significant reduction in the atherosclerotic lesion
area compared to the water-treated group reporting significant anti-oxidant capacities of all
pomegranate extracts.
The principal mechanisms of action of pomegranate juice may include: increased serum an‐
ti-oxidant capacity, decreased plasma lipids and lipid peroxidation, decreased ox-LDL up‐
take by macrophages, decreased intima-media thickness, decreased atherosclerotic lesion
areas, decreased inflammation and decreased systolic blood pressure, thereby reducing/
inhibiting the progression of atherosclerosis and the subsequent potential development of
CVDs [30,50].
On the basis of limited safety data, high doses of pomegranate polyphenol extracts may
have some deleterious effects: gastric irritation, allergic reactions, including pruritus, urtica‐
ria, angioedema, rhinorrhea, bronchospasm, dyspnea and red itchy eyes. Moreover, dried
pomegranate peel may contain aflatoxin, a potent hepatocarcinogen; thus, it should be used
cautiously by patients who have hepatic dysfunction or who are taking other hepatotoxic
agents. Pomegranate may also increase the risk for rhabdomyolysis during statin therapy, as
a result of intestinal CYP3A4 inhibition and increased absorption of active drugs [49].
10. Wine
The last two decades have seen renewed interest in the health benefits of wine, as documented
by increasing research and several epidemiologic observations showing that moderate wine
drinkers have lower cardiovascular mortality rates than heavy drinkers or teetotalers. Most of
the beneficial effects of wine against CVDs have been attributed to the presence in red wine of
resveratrol and other polyphenols. Wines contain polyphenolic compounds that can be rough‐
ly classified in flavonoid and non flavonoid compounds; both classes of compounds have been
implicated in the protective effects of wine on the cardiovascular system. Resveratrol is one of
the most biologically active polyphenols contained in wine.
Moderate wine intake reduces cardiovascular risk [51]. In addition, it is known that alcohol
favourably modifies the lipid pattern by decreasing total plasma cholesterol, in particular
LDL, and by increasing HDL. Cardiovascular risk reduction seems to be linked largely to
the effect of non-alcoholic components, mainly resveratrol and other polyphenols, on the
vascular wall and blood cells and a great part of the beneficial effects of resveratrol on vas‐
cular function are due to its anti-oxidant effects.
The effect of resveratrol and other wine polyphenols on oxidative stress has been scarcely
explored in humans and only a few studies have analyzed the effects of wine supplementa‐
tion on indexes of oxidation in vivo [36].
Current Trends in Atherogenesis14
Figure 8. Main polyphenols in wine. * Polyphenols contained only in white wine. Modified from [36].
11. Olive oil
A high intake of some unsaturated fatty acid and/or anti-oxidant compounds can both re‐
duce pro-atherogenic risk factors and the susceptibility of the vascular wall to pro-inflam‐
matory and pro-atherogenic triggers.
Many Authors started to recognize olive oil as one of the key elements in the cardioprotec‐
tion and longevity of inhabitants of Mediterranean regions. The healthful properties of olive
oil have been often attributed to its high content of monounsaturated fatty acids, namely
oleic acid [7]. However, it should be underlined that olive oil, unlike other vegetable oils,
contains high amounts of several micronutrient constituents, including polyphenolic com‐
pounds (100– 1000 mg/kg) [10].
The major phenolic compounds in olive oil are: simple phenols (i.e., hydroxytyrosol, tyro‐
sol); polyphenols (oleuropein glucoside); secoiridoids, dialdehydic form of oleuropein and
ligstroside lacking a carboxymethyl group and the aglycone form of oleuropein glucoside
and ligstroside and lignans. Around 80% or more of the olive oil phenolic compounds are
lost in the refination process, thus, their content is higher in virgin olive oil (around 230 mg/
kg) than in other olive oils.
Olive oil supplementation (50 mg/day) to the diet enriched LDL with oleic acid and signifi‐
cantly reduced human LDL susceptibility to in vitro oxidation, thus making them signifi‐
cantly less atherogenic. In part, this reflects the lesser susceptibility of monounsaturated
fatty acids to lipid peroxidation compared with that of polyunsaturated fatty acids, which
are particularly prone to peroxidation due to the greater number of double bonds [10,52].
Olive oil consumption could reduce oxidative damage, on one hand, due to its richness in
oleic acid and, on the other hand, due to its minor components of the olive oil particularly
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the phenolic compounds. The phenolic content in virgin olive oil could reduce the lipid oxi‐
dation and inhibit platelet-induced aggregation [53].
Moreover, olive oil minor components have also been involved in the anti-oxidant activity
of olive oil. Some components of the unsaponifiable fraction, such as squalene, β-sitosterol
or triterpenes, have been shown to display anti-oxidant and chemopreventive activities and
capacity to improve endothelial function decreasing the expression of cell adhesion mole‐
cules and increasing vasorelaxation [54].
Olive oil phenolic compounds are able to bind the LDL lipoprotein and to protect other phe‐
nolic compounds bound to LDL from oxidation. The role of phenolic compounds from olive
oil on DNA oxidative damage remains controversial and perhaps more sensitive methods
would be required to detect differences among the types of olive oil consumed. Further
studies are required to establish the potential benefits of olive oil and those of its minor com‐
ponents on DNA oxidative damage.
One of the most well known and important characteristic of the Mediterranean diet is the
presence of virgin olive oil as the principal source of energy from fat. In contrast to other
edible oils with a similar fatty composition, like sunflower, soybean and rapeseed canola
oils, virgin olive oil is a natural juice, while the seed oils must be refined before consump‐
tion, thus changing its original composition during this process. Virgin olive oils are those
obtained from the olives solely by mechanical or other physical means under conditions that
do not lead alteration in the oil. The olives have not undergone any treatment other than
washing, decantation, centrifugation or filtration [53].
Virgin olive oil is a source of healthy unsaturated fatty acids and hundreds of micronu‐
trients, especially anti-oxidants, as phenol compounds, vitamin E and carotenes.
Results of the randomized cross-over clinical trials performed in humans on the anti-oxidant
effects of olive oil phenolic compounds are controversial. The protective effects on lipid oxi‐
dation in these trials have been better displayed in oxidative stress conditions, i.e. males,
submitted to a very strict anti-oxidant diet, hyperlipidaemic or peripheral vascular disease
patients. Carefully controlled studies in appropriate populations, or with a large sample
size, are urgently required to definitively establish the in vivo anti-oxidant properties of the
active components of virgin olive oil [55].
12. Oligoelements in water
Epidemiological studies have revealed both a higher incidence of CVDs and cerebrovascular
mortality in soft water areas and a negative correlation between water hardness and cardio‐
vascular mortality [56,57]. Actually, there is not enough evidence to determine whether hard
water contains protective substances not present in soft water or if there are detrimental
substances in soft water.
Water contains oligominerals, such as calcium, magnesium, cobalt, lithium, vanadium, sili‐
con, copper, iron, zinc and manganese, that are some important factors in reducing the risk
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of CVD onset. On the other hand, elements like cadmium, lead, silver, mercury and thallium
are considered to be harmful [58].
Magnesium deficiency is considered to be a risk factor of CVDs, in fact its supplementation
delays the onset of atherosclerosis or hinders its development. On the other hand, silicon is a
major trace element in animal diets and humans ingest between 20-50 mg/day of silicon
with the Western diet [59]. Main dietary sources are whole grain cereals and their products
(including beer), rice, some fruits and vegetables and drinking water, especially bottled min‐
eral waters with geothermal and volcanic origin [60]. Numerous studies showed that silicon
has a role in maintaining the integrity, the stability and the elastic properties of arterial walls
[61,62] and postulated silicon as a protective factor against the development of age-linked
vascular diseases, such as atherosclerosis and hypertension [62,63].
In addition, vanadium is considered to have anti-atherosclerotic properties; lithium can also
inhibit the synthesis of cholesterol, but has an atherogenous activity that can be inhibited by
supplementation with appropriate quantities of calcium. A copper-deficient diet can induce
hypercholesterolemia and hypertriglyceridemia that is, in turn, intensified by high levels of
dietary zinc [58,64].
On the basis of these limited data, intakes of silicon, magnesium and vanadium in water and
avoiding exposure to cadmium and lead are important elements of the prophylaxis of
CVDs, so hard water has positive health effects and should not be replaced by drinking wa‐
ter with insufficient amounts of beneficial elements [58]. It is important to remember also
that water has small contribution of mineral trace respect to total dietary intake (7% from
liquid vs 93% from solid food) [58,65].
13. Melatonin supplementation
Melatonin, an endogenously produced indoleamine, is a remarkably functionally pleiotropic
molecule [66] which functions as a highly effective anti-oxidant and free radical scavenger
[67,68]. Endogenously produced and exogenously administered melatonin has beneficial ac‐
tions on the cardiovascular system [69,70,71].
Exogenously administered melatonin is quickly distributed throughout the organism; it may
cross all morphophysiological barriers and it enters cardiac and vascular cells easily. High‐
est intracellular concentration of melatonin seem to be in the mitochondria; this is especially
important as the mitochondria are a major site of free radicals and oxidative stress genera‐
tion. Moreover, melatonin administration in a broad range of concentration, both by the oral
and intravenous routes, has proven to be safe for human studies [72,73].
Melatonin itself appears to have an atheroprotective activity during LDL oxidation and also
melatonin’s precursors and breakdown products inhibit LDL oxidation, comparable to vita‐
min E. Because of its lipophilic and nonionized nature, melatonin should enter the lipid
phase of the LDL particles and prevent lipid peroxidation [9] and may also augments en‐
dogenous cholesterol clearance.
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Melatonin also counteracts the cell oxidative burden indirectly by stimulating the produc‐
tion of cell ROS detoxifying enzymes, specially glutathione peroxidase, glutathione reduc‐
tase and superoxide desmutase. Melatonin besides being a more effective anti-oxidant than
resveratrol can reverse the pro-oxidant DNA damage induced in low concentration of re‐
sveratrol, when added in combination [74].
Moreover, 6-hydroxymelatonin, the main in vivo metabolite of melatonin, and its precursor,
N-acetyl-5-hydroxytryptamine, were potent in reducing in vitro LDL peroxidation. The abili‐
ty of the parent molecule melatonin as well as its metabolites to function in radical detoxifi‐
cation greatly increases its ability to limit oxidative abuse at many levels within cells [9].
Therefore it can be suggested that although melatonin per se would have physiologically or
pharmacologically effects to inhibit in vivo LDL oxidation, its action sinergically with its
main catabolite would be more active [75]. Melatonin may exert protective and benefical ef‐
fects against CVDs reducing the risk of atherosclerosis and hypertension [9].
It is important to underline that the recent discovery of melatonin in grapes [74] opens new
pespectives in the field of natural anti-oxidative atheroprotective strategies.
14. Vitamins
Vitamin C is a water-soluble vitamin and is believed to regenerate vitamin E from its oxi‐
dized state back to its activated state. The principal sources of vitamin C are citrus fruits,
tomatoes and potatoes. Natural vitamin E is a mixture of tocopherols and tocotrienols syn‐
thesized only by plants and the natural sources are vegetal oils. In fact, olive oil contains vi‐
tamin E and many of its beneficial effects are attributed to this constituent.
Vitamin E acts as a chain-breaking anti-oxidant for LDL lipids [27]. In vitro enrichment of
LDL in vitamin E drastically increases their resistance to oxidative stress and it has also been
reported to inhibit the cytotoxicity of ox-LDL toward cultured endothelial cells. Vitamin E
has been reported to retard atherosclerosis progression in certain arteries of primates fed an
atherosclerosis diet. In humans, both women and men, exhibited reduced vascular disease
parameters [75], beneficial effects in the reduction of risk of onset and progression of athero‐
sclerosis, due to its inhibition of LDL oxidation and association with molecular modulation
of the interaction of immune and endothelial cells. A long term supplementation with vita‐
min E in hypercholesterolemic patients and/or chronic smokers increase levels of autoanti‐
bodies against ox-LDL. There is also a quite convincing evidence from in vitro studies that
vitamin C strongly inhibits LDL oxidation [27].
It is important to underline that there are no definite recommendations on the dose and du‐
ration of supplementation with vitamins in human. Although, high dietary intake of fruit
and vegetables is associated with a reduction in the incidence of atherosclerosis, stroke and
cardiovascular mortality in general [27]. Moreover, epidemiologic studies have reported
that high dietary intake of foods rich in vitamin E, vitamin C and β-carotene have been in‐
versely associated with the incidence of CVDs [35].
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Actually, it is difficult to conclude that a clinical benefit of anti-oxidants in CVD is estab‐
lished. Thus, it is necessary to clarify why anti-oxidants showed their beneficial effects in
vitro,  whereas  less  satisfactory  results  were  observed in  some,  although not  all,  clinical
conditions [40].
15. HDL-based diet
It is well known that LDL are crucial to the development of atherosclerotic lesions, whereas
HDL are inhibitors of the process, so the primary focus of pharmaceutical lipid modulation
is reduced LDL; this strategy has reduced cardiovascular morbidity and mortality by up to
25% [76].
Recent studies also suggest that HDL inhibits oxidation, prevents the expression of inflam‐
matory mediators and the expansion of pro-atherogenic myeloid cells and reduces the ex‐
pression of pro-coagulant enzymes, each of which may contribute in smaller ways to
atheroprotective effects [77].
The synthesis and release of HDL into the peripheral vasculature is the first step in reverse
cholesterol transport that is proposed to be a major mechanism by which HDL mediates its
atheroprotective effects [78]. However, HDL possesses multiple anti-atherosclerotic proper‐
ties in addition to reverse cholesterol transport. HDL acts as a transporter of a variety of fat-
soluble vitamins, including vitamin E, and also as a natural anti-oxidant protecting for LDL
in a multifactorial manner. Moreover, HDL are associated with enzymes with anti-oxidant
capacity, like paraoxonase that is a major contributor to the anti-oxidant activity of HDL
[78]. Paraoxonase is synthesized in the liver and released into the circulation, where it be‐
comes closely associated with HDL.
HDL has also been demonstrated to improve endothelial function, maintain the integrity of
vascular endothelium and may induce the production of vasodilators, such as prostacyclin,
by the endothelium. HDL has also been demonstrated to exhibit anti-thrombotic and anti-
inflammatory activities.
The combination of a low saturated fat diet and increased exercise raises HDL levels by 5–
14% and lowers triglyceride, LDL and total cholesterol levels by 4–18%, 7–15% and 7-18%,
respectively. Thus, simple lifestyle measures including a correct diet and increased activity
represent a cost-effective and low-risk intervention that is associated with a range of health
benefits [76].
There is considerable interest at present in the possible therapeutic effects of elevating HDL
levels to capitalize on their vasculoprotective effects. Although, clinical evidence to date has
provided inconsistent results and suggests that raising HDL levels may not be the straight‐
forward answer to atheroprotection [79,80]; HDL-based therapies, also combined with other
atheroprotective strategies, may be a valide future atheroprotective approach.




As a result of increased understanding of the characteristics and production of ROS and
oxidative stress and demonstrated a link either directly or indirectly to atherosclerosis, the
reduction of ROS or decreasing their rate of production may delay the onset and progres‐
sion of atherosclerosis. Aging promotes physiological changes, such as oxidative stress, in‐
flammation  and endothelial  dysfunction  strictly  associated  with  the  pathophysiology  of
atherosclerosis.  Actually,  compelling  evidence  indicates  that  increased  consumption  of
correct  diet  containing nutritive and non-nutritive compounds with anti-oxidant proper‐
ties may contribute to the improvement of the quality of life by delaying onset and reduc‐
ing the risk of CVDs and, in particular, the development of an atheroprotective strategies
acting on oxidative stress involved in the pathogenesis  of  atherosclerosis  and with little
toxicity or adverse effects may provide an ideal simil-therapeutic treatment against athero‐
sclerosis. Actually, cardiovascular prevention and treatment strategies should consider the
simple, direct and inexpensive dietary approach as a first line approach to the burgeoning
burden of  CVDs,  alone or in combination with pharmacological  treatments.  In this  con‐
text,  wine, tea,  fruit  and olive oil  received much attention, because they are particularly
rich in natural anti-oxidants.
However, a better understanding of the oxidative stress-dependent signal transduction
mechanisms, their localization, and the integration of both ROS-dependent transcriptional
and signaling pathways in vascular pathophysiology is anyway a prerequisite for effective
pharmacological and non pharmacological interventions for cardiovascular protection from
oxidative stress.
In conclusion, the proposal that anti-oxidants may retard the progression of atherosclerosis
is very interesting and promising, but further studies are needed to better understand the
mechanisms that underline the biological effect of healthy life style.
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